Emily Taylor, despite being reunited with her husband from prison, becomes severely depressed with emotional episodes and suicide attempts. Her psychiatrist, Jonathan Banks, after conferring with her previous doctor, eventually prescribes an experimental new medication called Ablixa. The plot thickens when the side effects of the drug lead to Emily killing her husband in a "sleepwalking" state. With Emily plea-bargained into mental hospital confinement and Dr. Banks' practice crumbling around him, the case seems closed. However, Dr. Banks cannot accept full responsibility and investigates to clear his name. What follows is a dark quest that threatens to tear what's left of his life apart even as he discovers the diabolical truth of this tragedy. Written by Kenneth Chisholm (kchishol@)
A study by the Agency for Healthcare Research and Quality (AHRQ) found that in 2011, sedatives and hypnotics were a leading source for adverse drug events seen in the hospital setting. Approximately % of all ADEs present on admission and % of ADEs that originated during a hospital stay were caused by a sedative or hypnotic drug.  A second study by AHRQ found that in 2011, the most common specifically identified causes of adverse drug events that originated during hospital stays in the . were steroids, antibiotics, opiates/narcotics, and anticoagulants. Patients treated in urban teaching hospitals had higher rates of ADEs involving antibiotics and opiates/narcotics compared to those treated in urban nonteaching hospitals. Those treated in private, nonprofit hospitals had higher rates of most ADE causes compared to patients treated in public or private, for-profit hospitals. 
Note: The active ingredients in gynostemma are known as saponins. This large group of chemicals is characterized by their general ability to make soap-like suds when they are mixed with water and the mixture is shaken. Saponins may have many effects in the body, including positive ones such as improving immune function. Saponins may also have negative effects such as blocking the digestion of some nutrients. Gynostemma may contain over 80 different types of saponins. Because the content of saponins and other chemicals in gynostemma varies greatly depending on the species of the plant and the conditions under which it grows, standardizing gynostemma products is difficult. Standardization by the manufacturer should assure the same amount of active ingredient in every batch of the commercial preparation. Standardization of herbal products is not required by the . Food and Drug Administration (FDA), so not every gynostemma product that is available contains the same amounts of active ingredients.